Cai Lay Veterinary Pharmaceutical JSC (HNX:MKV)
Vietnam
· Delayed Price · Currency is VND 9,300.00
-200.00 (-2.11%)
At close: Jun 5, 2025
HNX:MKV Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2019 | FY 2018 | 2016 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2016 - 2017 |
| Revenue | 107,036 | 110,906 | 119,634 | 102,410 | 134,579 | Upgrade
|
| Revenue Growth (YoY) | -3.49% | -7.30% | 16.82% | -23.90% | 308.87% | Upgrade
|
| Cost of Revenue | 71,100 | 78,674 | 86,605 | 80,112 | 106,611 | Upgrade
|
| Gross Profit | 35,937 | 32,232 | 33,029 | 22,298 | 27,967 | Upgrade
|
| Selling, General & Admin | 23,877 | 21,539 | 21,086 | 14,185 | 21,187 | Upgrade
|
| Operating Expenses | 23,877 | 21,539 | 21,086 | 14,185 | 21,187 | Upgrade
|
| Operating Income | 12,060 | 10,693 | 11,942 | 8,113 | 6,780 | Upgrade
|
| Interest Expense | -38.53 | -481.41 | -1,182 | -3,891 | -4,920 | Upgrade
|
| Interest & Investment Income | 428.6 | 285.51 | 247.49 | 1.04 | 10.79 | Upgrade
|
| Currency Exchange Gain (Loss) | -8.44 | 9 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -3,245 | -2,754 | -3,507 | -1,721 | -1,553 | Upgrade
|
| Pretax Income | 9,197 | 7,752 | 7,502 | 2,502 | 318.07 | Upgrade
|
| Income Tax Expense | 1,872 | 1,550 | 1,598 | 735.25 | 535.61 | Upgrade
|
| Net Income | 7,324 | 6,201 | 5,904 | 1,767 | -217.54 | Upgrade
|
| Net Income to Common | 7,324 | 6,201 | 5,904 | 1,767 | -217.54 | Upgrade
|
| Net Income Growth | 18.11% | 5.04% | 234.10% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 5 | 5 | 5 | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 5 | 5 | - | - | Upgrade
|
| Shares Change (YoY) | - | 0.02% | - | - | - | Upgrade
|
| EPS (Basic) | 1464.86 | 1240.29 | 1181.00 | - | - | Upgrade
|
| EPS (Diluted) | 1464.86 | 1240.00 | 1181.00 | - | - | Upgrade
|
| EPS Growth | 18.13% | 5.00% | - | - | - | Upgrade
|
| Free Cash Flow | 5,597 | 24,406 | 7,031 | 21,909 | 7,465 | Upgrade
|
| Free Cash Flow Per Share | 1119.37 | 4881.24 | 1406.48 | - | - | Upgrade
|
| Gross Margin | 33.57% | 29.06% | 27.61% | 21.77% | 20.78% | Upgrade
|
| Operating Margin | 11.27% | 9.64% | 9.98% | 7.92% | 5.04% | Upgrade
|
| Profit Margin | 6.84% | 5.59% | 4.93% | 1.73% | -0.16% | Upgrade
|
| Free Cash Flow Margin | 5.23% | 22.01% | 5.88% | 21.39% | 5.55% | Upgrade
|
| EBITDA | 16,290 | 17,863 | 19,759 | 16,660 | 15,001 | Upgrade
|
| EBITDA Margin | 15.22% | 16.11% | 16.52% | 16.27% | 11.15% | Upgrade
|
| D&A For EBITDA | 4,231 | 7,171 | 7,816 | 8,546 | 8,220 | Upgrade
|
| EBIT | 12,060 | 10,693 | 11,942 | 8,113 | 6,780 | Upgrade
|
| EBIT Margin | 11.27% | 9.64% | 9.98% | 7.92% | 5.04% | Upgrade
|
| Effective Tax Rate | 20.36% | 20.00% | 21.30% | 29.38% | 168.40% | Upgrade
|
| Revenue as Reported | 107,036 | 110,906 | 119,634 | 102,410 | 134,579 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.